🚨 FDA Approves Generic Rivaroxaban (Xarelto) 2.5 mg. The FDA has approved the first generic version of rivaroxaban (Xarelto) 2.5 mg, a dosage used to reduce the risk of major cardiovascular events in people with coronary artery disease (CAD) and major thrombotic vascular events in people with peripheral artery disease (PAD). What this means: This approval provides more affordable options for patients with CAD and PAD who rely on rivaroxaban. ⚠️ Important note: This approval does not apply to pe

FDA has issued warning that Xarelto & Pradaxa can lead to Uncontrollable Internal Bleeding. The makers of Pradaxa have already agreed to pay around $650 Million to over 4,000 Victims. Those affected can use this link to see if they Qualify for any Cash Settlements or Financial Compensation. | Lawsuit Watch